Literature DB >> 18673368

Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain.

Micha M M Wilhelmus1, Sentini C S Grunberg, John G J M Bol, Anne-Marie van Dam, Jeroen J M Hoozemans, Annemieke J M Rozemuller, Benjamin Drukarch.   

Abstract

Alzheimer's disease (AD) is characterized by pathological lesions, in particular senile plaques (SPs), cerebral amyloid angiopathy (CAA) and neurofibrillary tangles (NFTs), predominantly consisting of self-aggregated proteins amyloid beta (Abeta) and tau, respectively. Transglutaminases (TGs) are inducible enzymes, capable of modifying conformational and/or structural properties of proteins by inducing molecular covalent cross-links. Both Abeta and tau are substrates for TG cross-linking activity, which links TGs to the aggregation process of both proteins in AD brain. The aim of this study was to investigate the association of transglutaminase 1 (TG1), transglutaminase 2 (TG2) and TG-catalyzed cross-links with the pathological lesions of AD using immunohistochemistry. We observed immunoreactivity for TG1, TG2 and TG-catalyzed cross-links in NFTs. In addition, both TG2 and TG-catalyzed cross-links colocalized with Abeta in SPs. Furthermore, both TG2 and TG-catalyzed cross-links were associated with CAA. We conclude that these TGs demonstrate cross-linking activity in AD lesions, which suggests that both TG1 and TG2 are likely involved in the protein aggregation processes underlying the formation of SPs, CAA and/or NFTs in AD brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18673368     DOI: 10.1111/j.1750-3639.2008.00197.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  35 in total

1.  Transglutaminase 2 protects against ischemic stroke.

Authors:  A J Filiano; J Tucholski; P J Dolan; G Colak; G V W Johnson
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

Review 2.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

Review 3.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

4.  Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.

Authors:  Micha M M Wilhelmus; Mieke de Jager; Annemieke J M Rozemuller; John Brevé; John G J M Bol; Richard L Eckert; Benjamin Drukarch
Journal:  J Pathol       Date:  2011-10-18       Impact factor: 7.996

5.  Effect of Some Growth Factors on Tissue Transglutaminase Overexpression Induced by β-Amyloid in Olfactory Ensheathing Cells.

Authors:  Rosalia Pellitteri; Roberta Bonfanti; Michela Spatuzza; Maria Teresa Cambria; Mariacristina Ferrara; Giuseppina Raciti; Agata Campisi
Journal:  Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.590

Review 6.  Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.

Authors:  Manuela Basso; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

Review 7.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

8.  Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Authors:  Gunnar Brinkmalm; Wei Hong; Zemin Wang; Wen Liu; Tiernan T O'Malley; Xin Sun; Matthew P Frosch; Dennis J Selkoe; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Dominic M Walsh
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

9.  Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains.

Authors:  Ji Zhang; Suqing Wang; Wei Huang; David A Bennett; Dennis W Dickson; Dengshun Wang; Rui Wang
Journal:  Mol Neurobiol       Date:  2015-09-19       Impact factor: 5.590

10.  The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer.

Authors:  Tiernan T O'Malley; William M Witbold; Sara Linse; Dominic M Walsh
Journal:  Biochemistry       Date:  2016-10-26       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.